
Digital health firm Pear considers future as cash dwindles
Company looks at possible sale, merger or licensing deal after making big layoffs last year.
Newsletters and Deep Dive digital magazine
Company looks at possible sale, merger or licensing deal after making big layoffs last year.
Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.
Pharma joins Eli Lilly, Novo Nordisk as it slashes the price of its widely-prescribed insulins.
Companies can't see eye to eye on the recently reported data from the CLEAR outcomes study.
The two-year ban reflects "serious breaches” of the trade organisation’s code of practice.
Editor's Picks
Newsletters and Deep Dive
digital magazine